Using the GEO (Gene Expression Omnibus) series GSE22862, Horie et al. [12] proved that RNAi-mediated targeting of transforming growth factor, beta 1 (TGFB1) ligands were beneficial for lung cancer treatment through its action on cancer and stromal cells. Here, TGFB1 is linked to cancer.